株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ポンペ病 - 市場洞察、疫学、市場予測 2028年

Pompe Disease - Market Insights, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 534816
出版日 ページ情報 英文 123 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
ポンペ病 - 市場洞察、疫学、市場予測 2028年 Pompe Disease - Market Insights, Epidemiology and Market Forecast - 2028
出版日: 2019年07月01日 ページ情報: 英文 123 Pages
概要

新興国10カ国(中国、台湾、サウジアラビア、アラブ首長国連邦、ロシア、トルコ、メキシコ、ブラジル、アルゼンチン、コロンビア)のポンペ病有病数は2017年に5万2,393人、その市場規模は1億1,626万米ドルと推計されています。

当レポートでは、新興国10カ国(中国、台湾、サウジアラビア、アラブ首長国連邦、ロシア、トルコ、メキシコ、ブラジル、アルゼンチン、コロンビア)におけるポンペ病市場を調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 主な洞察

第2章 ポンペ病市場の概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • タイプ
  • 遺伝的欠陥
  • 臨床症状
  • 原因
  • 兆候と症状
  • 病因
  • 診断

第4章 疫学および患者人口 - 地域別

  • 主な調査結果
  • キーオピニオンリーダー(KOL)の見解

第5章 新興国10カ国のポンペ病有病数

  • 新興国10カ国のポンペ病総有病数
  • 新興国10カ国のポンペ病診断数

第6章 ポンペ病の疫学:地域別

  • アジア
    • 中国
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
    • 台湾
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
  • 中東
    • サウジアラビア
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
    • アラブ首長国連邦
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
  • 東欧
    • ロシア
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
    • トルコ
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
  • ラテンアメリカ
    • メキシコ
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
    • ブラジル
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
    • アルゼンチン
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数
    • コロンビア
      • ポンペ病総出生数
      • ポンペ病出生数:病型別
      • ポンペ病総有病数
      • ポンペ病診断数

第7章 ポンペ病の治療と管理

第8章 アンメットニーズ

第9章 上市済み治療薬

  • ルミザイム:Genzyme
    • 製品説明
    • 規制のマイルストーン
    • 安全性と有効性
    • 売上高
    • 製品プロファイル

第10章 新薬

  • AT-GAA:Amicus Therapeutics
    • 製品説明
    • その他の開発活動
    • 規制のマイルストーン
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル

第11章 有望な候補薬

  • ACTUS-101:Actus Therapeutics
    • 製品説明
    • その他の開発活動
    • 規制のマイルストーン
    • 臨床開発
    • 製品プロファイル

第12章 新興国10カ国におけるポンペ病の分析

  • 主な調査結果
  • キーオピニオンリーダー(KOL)の見解
  • 新興国10カ国の市場規模
    • 市場規模:治療薬別

第13章 市場の見通し:国別

  • 新興国市場の見通し
  • 中国
    • 総市場規模
    • 市場規模:治療薬別
  • 台湾
  • サウジアラビア
  • アラブ首長国連邦
  • ロシア
  • トルコ
  • メキシコ
  • ブラジル
  • アルゼンチン
  • コロンビア

第14章 市場の成長要因

第15章 市場の障壁

第16章 付録

  • 調査方法

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalence of Pompe Disease in 10 Emerging Markets (2017-2028)
  • Table 2: Diagnosed Prevalence of Pompe Disease in 10 Emerging Markets (2017-2028)
  • Table 3: Total Live Birth Cases of Pompe Disease in China (2017-2028)
  • Table 4: Birth Prevalence of Pompe Disease by Onset Types in China (2017-2028)
  • Table 5: Total Prevalent Cases of Pompe Disease in China (2017-2028)
  • Table 6: Diagnosed Prevalence of Pompe Disease in China (2017-2028)
  • Table 7: Total Live Birth Cases of Pompe Disease in Taiwan (2017-2028)
  • Table 8: Birth Prevalence of Pompe Disease by Onset Types in Taiwan (2017-2028)
  • Table 9: Total Prevalent Cases of Pompe Disease in Taiwan (2017-2028)
  • Table 10: Diagnosed Prevalence of Pompe Disease in Taiwan (2017-2028)
  • Table 11: Total Live Birth Cases of Pompe Disease in Saudi Arabia (2017-2028)
  • Table 12: Birth Prevalence of Pompe Disease by Onset Types in Saudi Arabia (2017-2028)
  • Table 13: Total Prevalent Cases of Pompe Disease in Saudi Arabia (2017-2028)
  • Table 14: Diagnosed Prevalence of Pompe Disease in Saudi Arabia (2017-2028)
  • Table 15: Total Live Birth Cases of Pompe Disease in U.A.E. (2017-2028)
  • Table 16: Birth Prevalence of Pompe Disease by Onset Types in U.A.E. (2017-2028)
  • Table 17: Total Prevalent Cases of Pompe Disease in U.A.E. (2017-2028)
  • Table 18: Diagnosed Prevalence of Pompe Disease in U.A.E. (2017-2028)
  • Table 19: Total Live Birth Cases of Pompe Disease in Russia (2017-2028)
  • Table 20: Birth Prevalence of Pompe Disease by Onset Types in Russia (2017-2028)
  • Table 21: Total Prevalent Cases of Pompe Disease in Russia (2017-2028)
  • Table 22: Diagnosed Prevalence of Pompe Disease in Russia (2017-2028)
  • Table 23: Total Live Birth Cases of Pompe Disease in Turkey (2017-2028)
  • Table 24: Birth Prevalence of Pompe Disease by Onset Types in Turkey (2017-2028)
  • Table 25: Total Prevalent Cases of Pompe Disease in Turkey (2017-2028)
  • Table 26: Diagnosed Prevalence of Pompe Disease in Turkey (2017-2028)
  • Table 27: Total Live Birth Cases of Pompe Disease in Mexico (2017-2028)
  • Table 28: Birth Prevalence of Pompe Disease by Onset Types in Mexico (2017-2028)
  • Table 29: Total Prevalent Cases of Pompe Disease in Mexico (2017-2028)
  • Table 30: Diagnosed Prevalence of Pompe Disease in Mexico (2017-2028)
  • Table 31: Total Live Birth Cases of Pompe Disease in Brazil (2017-2028)
  • Table 32: Birth Prevalence of Pompe Disease by Onset Types in Brazil (2017-2028)
  • Table 33: Total Prevalent Cases of Pompe Disease in Brazil (2017-2028)
  • Table 34: Diagnosed Prevalence of Pompe Disease in Brazil (2017-2028)
  • Table 35: Total Live Birth Cases of Pompe Disease in Argentina (2017-2028)
  • Table 36: Birth Prevalence of Pompe Disease by Onset Types in Argentina (2017-2028)
  • Table 37: Total Prevalent Cases of Pompe Disease in Argentina (2017-2028)
  • Table 38: Diagnosed Prevalence of Pompe Disease in Argentina (2017-2028)
  • Table 39: Total Live Birth Cases of Pompe Disease in Colombia (2017-2028)
  • Table 40: Birth Prevalence of Pompe Disease by Onset Types in Colombia (2017-2028)
  • Table 41: Total Prevalent Cases of Pompe Disease in Colombia (2017-2028)
  • Table 42: Diagnosed Prevalence of Pompe Disease in Colombia (2017-2028)
  • Table 43: AT-GAA, Clinical Trial Description, 2019
  • Table 44: ACTUS-101, Clinical Trial Description, 2019
  • Table 45: Total Market Size of Pompe Disease in 10 Emerging Markets in USD Million (2017-2028)
  • Table 46: Total Market Size of Pompe Disease by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Table 47: Total Market Size of Pompe Disease in China, USD Million (2017-2028)
  • Table 48: China Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 49: Market Size of Pompe Disease in Taiwan, USD Million (2017-2028)
  • Table 50: Taiwan Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 51: Market Size of Pompe Disease in the Saudi Arabia, USD Million (2017-2028)
  • Table 52: Saudi Arabia Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 53: Market Size of Pompe Disease in U.A.E., USD Million (2017-2028)
  • Table 54: U.A.E. Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 55: Market Size of Pompe Disease in Russia, USD Million (2017-2028)
  • Table 56: Russia Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 57: Market Size of Pompe Disease in Turkey, USD Million (2017-2028)
  • Table 58: Turkey Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 59: Market Size of Pompe Disease in Mexico, USD Million (2017-2028)
  • Table 60: Mexico Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 61: Market Size of Pompe Disease in Brazil, USD Million (2017-2028)
  • Table 62: Brazil Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 63: Market Size of Pompe Disease in Argentina, USD Million (2017-2028)
  • Table 64: Argentina Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Table 65: Market Size of Pompe Disease in Colombia, USD Million (2017-2028)
  • Table 66: Colombia Market Size of Pompe Disease by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Comparison of normal physiology to pathophysiology in Pompe disease
  • Figure 2: Pathophysiology of late-onset Pompe disease
  • Figure 3: Diagnostic algorithm for infantile-onset Pompe disease.
  • Figure 4: Diagnostic algorithm for late-onset (> 1 year) Pompe disease.
  • Figure 5: Total Prevalence of Pompe Disease in 10 Emerging Markets (2017-2028)
  • Figure 6: Diagnosed Prevalence of Pompe Disease in 10 Emerging Markets (2017-2028)
  • Figure 7: Total Live Birth Cases of Pompe Disease in China (2017-2028)
  • Figure 8: Birth Prevalence of Pompe Disease by Onset Types in China (2017-2028)
  • Figure 9: Total Prevalent Cases of Pompe Disease in China (2017-2028)
  • Figure 10: Diagnosed Prevalence of Pompe Disease in China (2017-2028)
  • Figure 11: Total Live Birth Cases of Pompe Disease in Taiwan (2017-2028)
  • Figure 12: Birth Prevalence of Pompe Disease by Onset Types in Taiwan (2017-2028)
  • Figure 13: Total Prevalent Cases of Pompe Disease in Taiwan (2017-2028)
  • Figure 14: Diagnosed Prevalence of Pompe Disease in Taiwan (2017-2028)
  • Figure 15: Total Live Birth Cases of Pompe Disease in Saudi Arabia (2017-2028)
  • Figure 16: Birth Prevalence of Pompe Disease by Onset Types in Saudi Arabia (2017-2028)
  • Figure 17: Total Prevalent Cases of Pompe Disease in Saudi Arabia (2017-2028)
  • Figure 18: Diagnosed Prevalence of Pompe Disease in Saudi Arabia (2017-2028)
  • Figure 19: Total Live Birth Cases of Pompe Disease in U.A.E. (2017-2028)
  • Figure 20: Birth Prevalence of Pompe Disease by Onset Types in U.A.E. (2017-2028)
  • Figure 21: Total Prevalent Cases of Pompe Disease in U.A.E. (2017-2028)
  • Figure 22: Diagnosed Prevalence of Pompe Disease in U.A.E. (2017-2028)
  • Figure 23: Total Live Birth Cases of Pompe Disease in Russia (2017-2028)
  • Figure 24: Birth Prevalence of Pompe Disease by Onset Types in Russia (2017-2028)
  • Figure 25: Total Prevalent Cases of Pompe Disease in Russia (2017-2028)
  • Figure 26: Diagnosed Prevalence of Pompe Disease in Russia (2017-2028)
  • Figure 27: Total Live Birth Cases of Pompe Disease in Turkey (2017-2028)
  • Figure 28: Birth Prevalence of Pompe Disease by Onset Types in Turkey (2017-2028)
  • Figure 29: Total Prevalent Cases of Pompe Disease in Turkey (2017-2028)
  • Figure 30: Diagnosed Prevalence of Pompe Disease in Turkey (2017-2028)
  • Figure 31: Total Live Birth Cases of Pompe Disease in Mexico (2017-2028)
  • Figure 32: Birth Prevalence of Pompe Disease by Onset Types in Mexico (2017-2028)
  • Figure 33: Total Prevalent Cases of Pompe Disease in Mexico (2017-2028)
  • Figure 34: Diagnosed Prevalence of Pompe Disease in Mexico (2017-2028)
  • Figure 35: Total Live Birth Cases of Pompe Disease in Brazil (2017-2028)
  • Figure 36: Birth Prevalence of Pompe Disease by Onset Types in Brazil (2017-2028)
  • Figure 37: Total Prevalent Cases of Pompe Disease in Brazil (2017-2028)
  • Figure 38: Diagnosed Prevalence of Pompe Disease in Brazil (2017-2028)
  • Figure 39: Total Live Birth Cases of Pompe Disease in Argentina (2017-2028)
  • Figure 40: Birth Prevalence of Pompe Disease by Onset Types in Argentina (2017-2028)
  • Figure 41: Total Prevalent Cases of Pompe Disease in Argentina (2017-2028)
  • Figure 42: Diagnosed Prevalence of Pompe Disease in Argentina (2017-2028)
  • Figure 43: Total Live Birth Cases of Pompe Disease in Colombia (2017-2028)
  • Figure 44: Birth Prevalence of Pompe Disease by Onset Types in Colombia (2017-2028)
  • Figure 45: Total Prevalent Cases of Pompe Disease in Colombia (2017-2028)
  • Figure 46: Diagnosed Prevalence of Pompe Disease in Colombia (2017-2028)
  • Figure 47: Unmet Needs of Pompe Disease
  • Figure 48: Total Market Size of Pompe Disease in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 49: Total Market Size of Pompe Disease by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 50: Total Market Size of Pompe Disease in China, USD Million (2017-2028)
  • Figure 51: China Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 52: Market Size of Pompe Disease in Taiwan, USD Million (2017-2028)
  • Figure 53: Taiwan Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 54: Market Size of Pompe Disease in the Saudi Arabia, USD Million (2017-2028)
  • Figure 55: Saudi Arabia Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 56: Market Size of Pompe Disease in U.A.E., USD Million (2017-2028)
  • Figure 57: U.A.E. Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 58: Market Size of Pompe Disease in Russia, USD Million (2017-2028)
  • Figure 59: Russia Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 60: Market Size of Pompe Disease in Turkey, USD Million (2017-2028)
  • Figure 61: Turkey Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 62: Market Size of Pompe Disease in Mexico, USD Million (2017-2028)
  • Figure 63: Mexico Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 64: Market Size of Pompe Disease in Brazil, USD Million (2017-2028)
  • Figure 65: Brazil Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 66: Market Size of Pompe Disease in Argentina, USD Million (2017-2028)
  • Figure 67: Argentina Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 68: Market Size of Pompe Disease in Colombia, USD Million (2017-2028)
  • Figure 69: Colombia Market Size of Pompe Disease by Therapies in USD Million (2017-2028)
  • Figure 70: Market Drivers
  • Figure 71: Market Barriers
目次
Product Code: DIMI0172

DelveInsight's 'Pompe Disease - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the emerging market trends of Pompe Disease in the Asia (China and Taiwan), Middle East (Saudi Arabia and U.A.E.), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Colombia).

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pompe Disease from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • Asia (China and Taiwan)
  • Middle East (Saudi Arabia and U.A.E.)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina and Colombia)

Study Period: 2017-2028

Pompe Disease - Disease Understanding and Treatment Algorithm

The DelveInsight Pompe Disease market report gives the thorough understanding of the Pompe Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pompe Disease in the Asia (China and Taiwan), Middle East (Saudi Arabia and U.A.E.), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Colombia).

Pompe Disease Epidemiology

The Pompe Disease epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging markets. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Live Birth Cases of Pompe Disease, Birth Prevalence of Pompe Disease by Onset Types, Total Prevalent Cases of Pompe Disease and Diagnosed Prevalence of Pompe Disease) scenario of Pompe Disease in the 10EM covering Asia (China and Taiwan), Middle East (Saudi Arabia and U.A.E.), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Colombia) from 2017-2028.

According to DelveInsight, total prevalent population of Pompe Disease in 10 emerging markets was found to be 52,393 in 2017. 

Pompe Disease Drug Chapters

This segment of the Pompe Disease report encloses the detailed analysis of Treatment Algorithm, Current Treatment, and Medical Practices Treatment of Pompe Disease. The treatment of Pompe disease is disease-specific, symptomatic, and supportive. Treatment requires the coordinated efforts of a team of specialists with expertise in treating neuromuscular disorders. Pediatricians or internists, neurologists, orthopedists, cardiologists, dieticians, and other healthcare professionals may need to systematically and comprehensively plan an affect child's treatment. Genetic counseling is of utmost importance for affected individuals and their families. There are only two treatment regimens available for this disease: Enzyme Replacement Therapy and Supportive Therapies.

The report also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. At present, the only therapeutic treatment contributing towards the market size of Pompe Disease includes: Lumizyme (alglucosidase alfa), is an enzyme replacement therapy produced by recombinant DNA technology. It provides an exogenous source of acid α glucosidase (GAA), an essential lysosomal enzyme that is deficient or absent in patients with Pompe disease, leading to intralysosomal glycogen accumulation. A detailed chapter for upcoming/emerging therapies like AT-GAA (Amicus Therapeutics) and ACTUS-101 (Actus Therapeutics) have also been covered in the report.

Pompe Disease Market Outlook

The Pompe Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Pompe Disease in 10EM was found to be USD 116.26 million in 2017.

Pompe Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pompe Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Pompe Disease Report Key Strengths

  • 10 Year Forecast
  • 10EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Pompe Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Pompe Disease emerging market
  • Organize sales and marketing efforts by identifying the best opportunities for Pompe Disease market
  • To understand the future market competition in the Pompe Disease market.

Table of Contents

1. Key Insights

2. Pompe Disease Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Pompe Disease in 2017
  • 2.2. Market Share (%) Distribution of Pompe Disease in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Types
  • 3.3. Genetic defects
  • 3.4. Clinical Manifestations
  • 3.5. Causes
  • 3.6. Signs and Symptoms
  • 3.7. Pathogenesis
  • 3.8. Diagnosis

4. Epidemiology and Patient Population - By Region

  • 4.1. Key Findings
  • 4.2. KOL Views

5. Ten Emerging Markets (EM) Total Prevalent Patient Population of Pompe Disease

  • 5.1. Total Prevalence of Pompe Disease in 10 Emerging Markets
  • 5.2. Diagnosed Prevalence of Pompe Disease in 10 Emerging Markets

6. Region Wise-Epidemiology of Pompe Disease

  • 6.1. Asia (China and Taiwan)
    • 6.1.1. Assumptions and Rationale
  • 6.2. China
    • 6.2.1. Total Live Birth Cases of Pompe Disease in China
    • 6.2.2. Birth Prevalence of Pompe Disease by Onset Types in China
    • 6.2.3. Total Prevalent Cases of Pompe Disease in China
    • 6.2.4. Diagnosed Prevalence of Pompe Disease in China
  • 6.3. Taiwan
    • 6.3.1. Total Live Birth Cases of Pompe Disease in Taiwan
    • 6.3.2. Birth Prevalence of Pompe Disease by Onset Types in Taiwan
    • 6.3.3. Total Prevalent Cases of Pompe Disease in Taiwan
    • 6.3.4. Diagnosed Prevalence of Pompe Disease in Taiwan
  • 6.4. Middle East (Saudi Arabia and U.A.E.)
    • 6.4.1. Assumptions and Rationale
  • 6.5. Saudi Arabia
    • 6.5.1. Total Live Birth Cases of Pompe Disease in Saudi Arabia
    • 6.5.2. Birth Prevalence of Pompe Disease by Onset Types in Saudi Arabia
    • 6.5.3. Total Prevalent Cases of Pompe Disease in Saudi Arabia
    • 6.5.4. Diagnosed Prevalence of Pompe Disease in Saudi Arabia
  • 6.6. U.A.E.
    • 6.6.1. Total Live Birth Cases of Pompe Disease in U.A.E.
    • 6.6.2. Birth Prevalence of Pompe Disease by Onset Types in U.A.E.
    • 6.6.3. Total Prevalent Cases of Pompe Disease in U.A.E.
    • 6.6.4. Diagnosed Prevalence of Pompe Disease in U.A.E.
  • 6.7. Eastern Europe (Russia and Turkey)
    • 6.7.1. Assumptions and Rationale
  • 6.8. Russia
    • 6.8.1. Total Live Birth Cases of Pompe Disease in Russia
    • 6.8.2. Birth Prevalence of Pompe Disease by Onset Types in Russia
    • 6.8.3. Total Prevalent Cases of Pompe Disease in Russia
    • 6.8.4. Diagnosed Prevalence of Pompe Disease in Russia
  • 6.9. Turkey
    • 6.9.1. Total Live Birth Cases of Pompe Disease in Turkey
    • 6.9.2. Birth Prevalence of Pompe Disease by Onset Types in Turkey
    • 6.9.3. Total Prevalent Cases of Pompe Disease in Turkey
    • 6.9.4. Diagnosed Prevalence of Pompe Disease in Turkey
  • 6.10. LATAM (Mexico, Brazil, Argentina and Colombia)
    • 6.10.1. Assumptions and Rationale
  • 6.11. Mexico
    • 6.11.1. Total Live Birth Cases of Pompe Disease in Mexico
    • 6.11.2. Birth Prevalence of Pompe Disease by Onset Types in Mexico
    • 6.11.3. Total Prevalent Cases of Pompe Disease in Mexico
    • 6.11.4. Diagnosed Prevalence of Pompe Disease in Mexico
  • 6.12. Brazil
    • 6.12.1. Total Live Birth Cases of Pompe Disease in Brazil
    • 6.12.2. Birth Prevalence of Pompe Disease by Onset Types in Brazil
    • 6.12.3. Total Prevalent Cases of Pompe Disease in Brazil
    • 6.12.4. Diagnosed Prevalence of Pompe Disease in Brazil
  • 6.13. Argentina
    • 6.13.1. Total Live Birth Cases of Pompe Disease in Argentina
    • 6.13.2. Birth Prevalence of Pompe Disease by Onset Types in Argentina
    • 6.13.3. Total Prevalent Cases of Pompe Disease in Argentina
    • 6.13.4. Diagnosed Prevalence of Pompe Disease in Argentina
  • 6.14. Colombia
    • 6.14.1. Total Live Birth Cases of Pompe Disease in Colombia
    • 6.14.2. Birth Prevalence of Pompe Disease by Onset Types in Colombia
    • 6.14.3. Total Prevalent Cases of Pompe Disease in Colombia
    • 6.14.4. Diagnosed Prevalence of Pompe Disease in Colombia

7. Treatment and Management of Pompe Disease

8. Unmet Needs

9. Marketed Drugs

  • 9.1. Lumizyme: Genzyme
    • 9.1.1. Product Description
    • 9.1.2. Regulatory Milestones
    • 9.1.3. Safety and Efficacy
    • 9.1.4. Sales
    • 9.1.5. Product Profile

10. Emerging Therapies

  • 10.1. AT-GAA: Amicus Therapeutics
    • 10.1.1. Product Description
    • 10.1.2. Other Developmental Activities
    • 10.1.3. Regulatory Milestones
    • 10.1.4. Clinical Development
    • 10.1.5. Safety and Efficacy
    • 10.1.6. Product Profile

11. Other Promising Candidates

  • 11.1. ACTUS-101: Actus Therapeutics
    • 11.1.1. Product Description
    • 11.1.2. Other Developmental Activities
    • 11.1.3. Regulatory Milestones
    • 11.1.4. Clinical Development
    • 11.1.5. Product Profile

12. Pompe Disease: 10 EM Analysis

  • 12.1. Key Findings
  • 12.2. KOL Views
  • 12.3. Market Size of Pompe Disease in 10 EM
    • 12.3.1. Market Size of Pompe Disease by Therapies

13. Market Outlook by Country

  • 13.1. Emerging Markets: Market Outlook
  • 13.2. China
    • 13.2.1. Total Market Size of Pompe Disease
    • 13.2.2. Market Size of Pompe Disease by Therapies
  • 13.3. Taiwan
    • 13.3.1. Total Market Size of Pompe Disease
    • 13.3.2. Market Size of Pompe Disease by Therapies
  • 13.4. Saudi Arabia
    • 13.4.1. Total Market Size of Pompe Disease
    • 13.4.2. Market Size of Pompe Disease by Therapies
  • 13.5. U.A.E.
    • 13.5.1. Total Market Size of Pompe Disease
    • 13.5.2. Market Size of Pompe Disease by Therapies
  • 13.6. Russia
    • 13.6.1. Total Market Size of Pompe Disease
    • 13.6.2. Market Size of Pompe Disease by Therapies
  • 13.7. Turkey
    • 13.7.1. Total Market Size of Pompe Disease
    • 13.7.2. Market Size of Pompe Disease by Therapies
  • 13.8. Mexico
    • 13.8.1. Total Market Size of Pompe Disease
    • 13.8.2. Market Size of Pompe Disease by Therapies
  • 13.9. Brazil
    • 13.9.1. Total Market Size of Pompe Disease
    • 13.9.2. Market Size of Pompe Disease by Therapies
  • 13.10. Argentina
    • 13.10.1. Total Market Size of Pompe Disease
    • 13.10.2. Market Size of Pompe Disease by Therapies
  • 13.11. Colombia
    • 13.11.1. Total Market Size of Pompe Disease
    • 13.11.2. Market Size of Pompe Disease by Therapies

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Back to Top